Key terms
About DOCS
Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DOCS news
Apr 01
4:09pm ET
Doximity short report concerns mostly already known, says Evercore ISI
Apr 01
9:50am ET
Doximity falls after Jehoshaphat questions sales growth in short report
Apr 01
9:45am ET
Jehoshaphat Research announces short position in Doximity
Mar 25
9:41am ET
Unusually active option classes on open March 25th
Feb 27
11:36pm ET
Doximity: A Steady Performer Amid Market Volatility and Operational Uncertainties
Feb 26
6:25am ET
Doximity initiated with a Market Perform at Leerink
Feb 09
9:47am ET
Doximity falls -10.2%
Feb 09
9:43am ET
Doximity price target raised to $27 from $25 at Wells Fargo
Feb 09
8:17am ET
Doximity (DOCS) Hold Rating Maintained Amid Growth Potential and Market Uncertainties
Feb 09
8:17am ET
Doximity Growth Prospects and Buy Rating Endorsed Amid Economic Caution
Feb 09
7:10am ET
Analysts Conflicted on These Healthcare Names: Doximity (DOCS) and AbbVie (ABBV)
Feb 09
6:48am ET
Doximity (DOCS) Maintains Hold Rating Amid Mixed Growth Signals and Potential Catalysts
Feb 09
6:47am ET
Doximity Sell Rating: Concerns Over Q4 Guidance and Market Share Outlook
Feb 09
6:43am ET
Doximity price target raised to $31 from $29 at Baird
Feb 08
4:05pm ET
Doximity sees FY24 revenue $473.3M-$474.3M, consensus $467.3M
Feb 08
4:04pm ET
Doximity sees Q4 revenue $115.9M-$116.9M, consensus $117.9M
Feb 08
4:04pm ET
Doximity reports Q3 EPS 24c, consensus 23c
Feb 08
3:19pm ET
Doximity options imply 11.0% move in share price post-earnings
Feb 07
7:47am ET
Doximity price target lowered to $29 from $32 at BofA
Feb 07
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Edwards Lifesciences (EW) and Doximity (DOCS)
Feb 01
6:37am ET
Doximity: Navigating Uncertainties in Digital Ad Market Growth and Competitive Challenges
Jan 24
7:41am ET
Analysts Conflicted on These Healthcare Names: Intuitive Surgical (ISRG), Madrigal Pharmaceuticals (MDGL) and Doximity (DOCS)
Jan 23
9:23am ET
Doximity price target raised to $32 from $29 at BofA
Jan 23
6:07am ET
Doximity’s Hold Rating Maintained Amidst Market Optimism and Growth Challenges
Jan 07
9:26pm ET
Truist Financial Keeps Their Hold Rating on Doximity (DOCS)
Jan 07
5:34am ET
BTIG Sticks to Their Hold Rating for Doximity (DOCS)
Apr 14
2:17pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Apr 12
3:20pm ET
SHAREHOLDER ALERT: Doximity Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Apr 08
7:30pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Doximity, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 06
1:18pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Apr 04
4:00pm ET
SHAREHOLDER ALERT: Doximity Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Apr 03
1:55pm ET
SHAREHOLDER ALERT: Doximity Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
DOCS Financials
Key terms
Ad Feedback
DOCS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DOCS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range